Acknowledgement
The authors wish to thank Ms. Juhee Lee from the Medical Research Collaborating Center (MRCC) of Seoul National University Medical School/Hospital for work on the statistical analysis.
References
- Terzi E, Iavarone M, Pompili M, Veronese L, Cabibbo G, Fraquelli M, et al. Contrast ultrasound LI-RADS LR-5 identifies hepatocellular carcinoma in cirrhosis in a multicenter restropective study of 1,006 nodules. J Hepatol 2018;68:485-492 https://doi.org/10.1016/j.jhep.2017.11.007
- Kono Y, Lyshchik A, Cosgrove D, Dietrich CF, Jang HJ, Kim TK, et al. Contrast enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS®): the official version by the American College of Radiology (ACR). Ultraschall Med 2017;38:85-86 https://doi.org/10.1055/s-0042-124369
- Schellhaas B, Strobel D. Tips and tricks in contrast-enhanced ultrasound (CEUS) for the characterization and detection of liver malignancies. Ultraschall Med 2019;40:404-424 https://doi.org/10.1055/a-0900-3962
- Quaia E, Calliada F, Bertolotto M, Rossi S, Garioni L, Rosa L, et al. Characterization of focal liver lesions with contrast-specific US modes and a sulfur hexafluoride-filled microbubble contrast agent: diagnostic performance and confidence. Radiology 2004;232:420-430 https://doi.org/10.1148/radiol.2322031401
- Kang HJ, Kim JH, Joo I, Han JK. Additional value of contrast-enhanced ultrasound (CEUS) on arterial phase non-hyperenhancement observations (≥2 cm) of CT/MRI for high-risk patients: focusing on the CT/MRI LI-RADS categories LR-3 and LR-4. Abdom Radiol (NY) 2020;45:55-63 https://doi.org/10.1007/s00261-019-02132-x
- Jang HJ, Kim TK, Burns PN, Wilson SR. CEUS: an essential component in a multimodality approach to small nodules in patients at high-risk for hepatocellular carcinoma. Eur J Radiol 2015;84:1623-1635 https://doi.org/10.1016/j.ejrad.2015.05.020
- Rossi S, Ghittoni G, Ravetta V, Torello Viera F, Rosa L, Serassi M, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol 2008;18:1749-1756 https://doi.org/10.1007/s00330-008-0931-z
- Kim TK, Noh SY, Wilson SR, Kono Y, Piscaglia F, Jang HJ, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 - a review of important differences compared to the CT/MRI system. Clin Mol Hepatol 2017;23:280-289 https://doi.org/10.3350/cmh.2017.0037
- Barr RG, Huang P, Luo Y, Xie X, Zheng R, Yan K, et al. Contrast-enhanced ultrasound imaging of the liver: a review of the clinical evidence for SonoVue and Sonazoid. Abdom Radiol (NY) 2020;45:3779-3788 https://doi.org/10.1007/s00261-020-02573-9
- Dietrich CF, Nolsoe CP, Barr RG, Berzigotti A, Burns PN, Cantisani V, et al. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver - update 2020 - WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultraschall Med 2020;41:562-585 https://doi.org/10.1055/a-1177-0530
- Quaia E. State of the art: LI-RADS for contrast-enhanced US. Radiology 2019;293:4-14 https://doi.org/10.1148/radiol.2019190005
- Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol 2019;25:245-263 https://doi.org/10.3350/cmh.2018.0090
- European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236 https://doi.org/10.1016/j.jhep.2018.03.019
- Aube C, Oberti F, Lonjon J, Pageaux G, Seror O, N'Kontchou G, et al. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int 2017;37:1515-1525 https://doi.org/10.1111/liv.13429
- Schellhaas B, Wildner D, Pfeifer L, Goertz RS, Hagel A, Neurath MF, et al. LI-RADS-CEUS-proposal for a contrast-enhanced ultrasound algorithm for the diagnosis of hepatocellular carcinoma in high-risk populations. Ultraschall Med 2016;37:627-634 https://doi.org/10.1055/s-0042-112221
- Kang HJ, Lee JM, Yoon JH, Han JK. Role of contrast-enhanced ultrasound as a second-line diagnostic modality in noninvasive diagnostic algorithms for hepatocellular carcinoma. Korean J Radiol 2021;22:354-365 https://doi.org/10.3348/kjr.2020.0973
- Lee JY, Minami Y, Choi BI, Lee WJ, Chou YH, Jeong WK, et al. The AFSUMB consensus statements and recommendations for the clinical practice of contrast-enhanced ultrasound using Sonazoid. Ultrasonography 2020;39:191-220 https://doi.org/10.14366/usg.20057
- Khalili K, Atri M, Kim TK, Jang HJ. Recognizing the role of the reticuloendothelial system in the late phase of US contrast agents. Radiology 2021;298:287-291 https://doi.org/10.1148/radiol.2020203245
- Shunichi S, Hiroko I, Fuminori M, Waki H. Definition of contrast enhancement phases of the liver using a perfluoro-based microbubble agent, perflubutane microbubbles. Ultrasound Med Biol 2009;35:1819-1827 https://doi.org/10.1016/j.ultrasmedbio.2009.05.013
- Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol 2007;33:318-325 https://doi.org/10.1016/j.ultrasmedbio.2006.08.008
- Hatanaka K, Kudo M, Minami Y, Maekawa K. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 2008;75 Suppl 1:42-47 https://doi.org/10.1159/000173423
- Hatanaka K, Kudo M, Minami Y, Ueda T, Tatsumi C, Kitai S, et al. Differential diagnosis of hepatic tumors: value of contrast-enhanced harmonic sonography using the newly developed contrast agent, Sonazoid. Intervirology 2008;51 Suppl 1:61-69 https://doi.org/10.1159/000122600
- Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-370 https://doi.org/10.1007/s12072-017-9799-9
- Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 2014;3:458-468 https://doi.org/10.1159/000343875
- Kang HJ, Lee JM, Yoon JH, Lee K, Kim H, Han JK. Contrast-enhanced US with sulfur hexafluoride and perfluorobutane for the diagnosis of hepatocellular carcinoma in individuals with high risk. Radiology 2020;297:108-116 https://doi.org/10.1148/radiol.2020200115
- Lv K, Zhai H, Jiang Y, Liang P, Xu HX, Du L, et al. Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions. Abdom Radiol (NY) 2021;46:4647-4659 https://doi.org/10.1007/s00261-021-03010-1
- Zhai HY, Liang P, Yu J, Cao F, Kuang M, Liu FY, et al. Comparison of Sonazoid and SonoVue in the diagnosis of focal liver lesions: a preliminary study. J Ultrasound Med 2019;38:2417-2425 https://doi.org/10.1002/jum.14940
- Korean Liver Cancer Association (KLCA), National Cancer Center (NCC). 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the management of hepatocellular carcinoma. Korean J Radiol 2019;20:1042-1113 https://doi.org/10.3348/kjr.2019.0140
- Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the study of liver diseases. Hepatology 2018;68:723-750 https://doi.org/10.1002/hep.29913
- American College of Radiology. LI-RADS® CT/MRI v2018. ACR.org Web site. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/LI-RADS-CT-MRI-v2018. Accessed March 5, 2022
- No authors listed. Minimum training requirements for the practice of medical ultrasound in Europe. Ultraschall Med 2010;31:426-427 https://doi.org/10.1055/s-0030-1263214
- Minami Y, Kudo M. Contrast-enhanced ultrasonography with Sonazoid in hepatocellular carcinoma diagnosis. Hepatoma Res 2020;6:46
- Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927;22:209-212 https://doi.org/10.1080/01621459.1927.10502953
- Guo Y, Wu V, Li X, Xu X, Cheng C. An illustration of rate difference estimation with sas in logistic regression. Proceedings of the PharmaSUG China 1st Conference; 2012 Jul 6-7; Beijing, China: PharmaSUG; 2012; p. 1-7
- Joo I, Lee JM, Lee DH, Jeon JH, Han JK. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol 2019;29:1724-1732 https://doi.org/10.1007/s00330-018-5727-1
- Joo I, Lee JM, Lee DH, Jeon JH, Han JK, Choi BI. Noninvasive diagnosis of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout? Eur Radiol 2015;25:2859-2868 https://doi.org/10.1007/s00330-015-3686-3
- Nam SJ, Yu JS, Cho ES, Kim JH, Chung JJ. High-flow haemangiomas versus hypervascular hepatocellular carcinoma showing "pseudo-washout" on gadoxetic acid-enhanced hepatic MRI: value of diffusion-weighted imaging in the differential diagnosis of small lesions. Clin Radiol 2017;72:247-254 https://doi.org/10.1016/j.crad.2016.09.020
- Kang HJ, Kim JH, Yoo J, Han JK. Diagnostic criteria of perfluorobutane-enhanced ultrasonography for diagnosing hepatocellular carcinoma in high-risk individuals: how is late washout determined? Ultrasonography 2022;41:530-542 https://doi.org/10.14366/usg.21172
- Hwang JA, Jeong WK, Min JH, Kim YY, Heo NH, Lim HK. Sonazoid-enhanced ultrasonography: comparison with CT/MRI liver imaging reporting and data system in patients with suspected hepatocellular carcinoma. Ultrasonography 2021;40:486-498 https://doi.org/10.14366/usg.20120
- Huang Y, Li W, Hu HT, Ruan SM, Xian MF, Xie XY, et al. Contrast-enhanced US diagnostic algorithm of hepatocellular carcinoma in patients with occult hepatitis B. Abdom Radiol (NY) 2022;47:608-617 https://doi.org/10.1007/s00261-021-03343-x
- Chen LD, Xu HX, Xie XY, Xie XH, Xu ZF, Liu GJ, et al. Intrahepatic cholangiocarcinoma and hepatocellular carcinoma: differential diagnosis with contrast-enhanced ultrasound. Eur Radiol 2010;20:743-753 https://doi.org/10.1007/s00330-009-1599-8
- Wildner D, Bernatik T, Greis C, Seitz K, Neurath MF, Strobel D. CEUS in hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in 320 patients - early or late washout matters: a subanalysis of the DEGUM multicenter trial. Ultraschall Med 2015;36:132-139 https://doi.org/10.1055/s-0034-1399147